Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
International Journal of Pharmacology
Year: 2019  |  Volume: 15  |  Issue: 2  |  Page No.: 200 - 208

Lipid-altering Efficacy of Ezetimibe/Simvastatin Compared with Rosuvastatin in Hypercholesterolaemic Patients: A Meta-Analysis

Yongming Liu, Nan Xia, Wanying Hu and Wei Zhao    

Abstract: Background and Objectives: Ezetimibe/simvastatin and rosuvastatin drugs are two effective lipid-lowering therapies for hypercholesterolemic patients. However, whether the effect of ezetimibe/simvastatin is superior to rosuvastatin is is still controversial. Therefore, the purpose of this study was to compare the efficacy between ezetimibe/simvastatin and rosuvastatin for hypercholesterolemia treatment by a meta-analysis. Materials and Methods: Based on the predefined searching strategy and selection criteria, the eligible studies were selected. The quality of included study was evaluated using Cochrane Collaboration’s tool. The out come assessments indexes including low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterin (HDL-C), total cholesterin (Total C), triglycerides (TG) and apolipoprotein B (Apo B) were analyzed. In addition, the sub-group analysis was performed for comparing the efficacy of two groups with different dosages and sensitivity analysis was performed. Results: Totally, six studies were collected in the present study. The quality of the included studies were relatively high. Ezetimibe/simvastatin might result in greater LDL-C, Total C, TG and Apo B reductions than rosuvastatin for hypercholesterolemia. In addition, compared with 10 mg/day rosuvastatin, 10/20 mg/day ezetimibe/simvastatin had a better clinical efficacy in lipid-lowering of LDL-C, Total C, TG and Apo B. Moreover, no obvious changes of lipid-altering were observed between the rosuvastatin 40 mg/day and ezetimibe/simvastatin 10/40 mg/day. Conclusion: Ezetimibe/simvastatin was recommended to administrate hypercholesterolemia for providing greater reductions of LDL-C, Total C, TG and Apo B than rosuvastatin. Ezetimibe/simvastatin 10/20 mg/day had a better clinical efficacy than rosuvastatin 10 mg/day, while ezetimibe/simvastatin 10/40 mg/day had the same lipid-lowering than rosuvastatin 40 mg/day.

Cited References   |    Fulltext    |   Related Articles   |   Back
   
 
 
 
  Related Articles

 
 
 
 
 
 
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility